IDEXX Laboratories (IDXX) Competitors $533.76 +0.40 (+0.07%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDXX vs. IQV, MCO, NVST, ZTS, BSX, SYK, MDT, BDX, EW, and RMDShould you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include IQVIA (IQV), Moody's (MCO), Envista (NVST), Zoetis (ZTS), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and ResMed (RMD). IDEXX Laboratories vs. Its Competitors IQVIA Moody's Envista Zoetis Boston Scientific Stryker Medtronic Becton, Dickinson and Company Edwards Lifesciences ResMed IQVIA (NYSE:IQV) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Does the media prefer IQV or IDXX? In the previous week, IDEXX Laboratories had 9 more articles in the media than IQVIA. MarketBeat recorded 32 mentions for IDEXX Laboratories and 23 mentions for IQVIA. IDEXX Laboratories' average media sentiment score of 1.09 beat IQVIA's score of 0.98 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 21 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IQV or IDXX? IQVIA currently has a consensus target price of $222.45, indicating a potential upside of 38.49%. IDEXX Laboratories has a consensus target price of $558.11, indicating a potential upside of 4.56%. Given IQVIA's higher possible upside, analysts clearly believe IQVIA is more favorable than IDEXX Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IQVIA 0 Sell rating(s) 7 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 2.75IDEXX Laboratories 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has better earnings & valuation, IQV or IDXX? IQVIA has higher revenue and earnings than IDEXX Laboratories. IQVIA is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIQVIA$15.41B1.80$1.37B$7.3421.88IDEXX Laboratories$3.93B10.92$887.87M$10.8249.33 Do institutionals & insiders believe in IQV or IDXX? 89.6% of IQVIA shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.6% of IQVIA shares are owned by company insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is IQV or IDXX more profitable? IDEXX Laboratories has a net margin of 22.76% compared to IQVIA's net margin of 8.61%. IDEXX Laboratories' return on equity of 57.35% beat IQVIA's return on equity.Company Net Margins Return on Equity Return on Assets IQVIA8.61% 29.16% 6.96% IDEXX Laboratories 22.76%57.35%26.97% Which has more volatility & risk, IQV or IDXX? IQVIA has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. SummaryIDEXX Laboratories beats IQVIA on 10 of the 16 factors compared between the two stocks. Get IDEXX Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDXX vs. The Competition Export to ExcelMetricIDEXX LaboratoriesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.96B$6.71B$5.54B$9.13BDividend YieldN/A1.28%5.06%4.01%P/E Ratio49.3726.4628.2819.58Price / Sales10.9262.34373.3579.96Price / Cash42.9120.6824.7227.50Price / Book27.404.718.265.55Net Income$887.87M$174.76M$3.19B$252.28M7 Day Performance-2.16%1.45%5.27%2.99%1 Month Performance2.12%2.12%9.19%11.65%1 Year Performance8.33%6.84%30.12%17.15% IDEXX Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDXXIDEXX Laboratories3.554 of 5 stars$533.77+0.1%$558.11+4.6%+8.2%$42.96B$3.93B49.3711,000Positive NewsAnalyst UpgradeIQVIQVIA4.9232 of 5 stars$162.57-1.0%$226.32+39.2%-27.4%$28.12B$15.41B22.1588,000Analyst RevisionMCOMoody's4.7153 of 5 stars$502.51-0.5%$520.73+3.6%+12.0%$90.40B$7.09B43.3915,838Positive NewsNVSTEnvista3.2638 of 5 stars$19.66-3.6%$20.23+2.9%+25.9%$3.33B$2.51B-3.0112,300ZTSZoetis4.9187 of 5 stars$156.98-1.4%$212.13+35.1%-13.5%$69.89B$9.26B28.1813,800Positive NewsBSXBoston Scientific4.6336 of 5 stars$103.75-0.5%$116.09+11.9%+32.8%$153.49B$16.75B75.7353,000SYKStryker4.7959 of 5 stars$392.26-0.8%$427.30+8.9%+14.7%$149.72B$22.60B53.0153,000Positive NewsMDTMedtronic4.5876 of 5 stars$87.73-0.7%$97.87+11.6%+15.5%$112.52B$33.54B24.2395,000Positive NewsAnalyst ForecastBDXBecton, Dickinson and Company4.9503 of 5 stars$172.92-1.8%$219.22+26.8%-23.2%$49.56B$20.18B33.0074,000Positive NewsEWEdwards Lifesciences4.3701 of 5 stars$76.64-0.2%$80.20+4.6%-14.2%$44.96B$5.44B10.9515,800Positive NewsRMDResMed4.161 of 5 stars$256.16-0.3%$259.33+1.2%+24.1%$37.56B$4.69B28.759,980Positive News Related Companies and Tools Related Companies IQV Alternatives MCO Alternatives NVST Alternatives ZTS Alternatives BSX Alternatives SYK Alternatives MDT Alternatives BDX Alternatives EW Alternatives RMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDXX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEXX Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
